<code id='D071659378'></code><style id='D071659378'></style>
    • <acronym id='D071659378'></acronym>
      <center id='D071659378'><center id='D071659378'><tfoot id='D071659378'></tfoot></center><abbr id='D071659378'><dir id='D071659378'><tfoot id='D071659378'></tfoot><noframes id='D071659378'>

    • <optgroup id='D071659378'><strike id='D071659378'><sup id='D071659378'></sup></strike><code id='D071659378'></code></optgroup>
        1. <b id='D071659378'><label id='D071659378'><select id='D071659378'><dt id='D071659378'><span id='D071659378'></span></dt></select></label></b><u id='D071659378'></u>
          <i id='D071659378'><strike id='D071659378'><tt id='D071659378'><pre id='D071659378'></pre></tt></strike></i>

          focus

          focus

          author:knowledge    Page View:96162
          Sammy Kimball for STAT

          Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

          advertisement

          For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Cassava reveals details — and problems — with Alzheimer's study
          Cassava reveals details — and problems — with Alzheimer's study

          MollyFerguson/STATCassavaScienceshaslongclaimeditsexperimentaldrug,calledsimufilam,slowsthecognitive

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Snackable artificial intelligence, expert AI, and the pharma industry

          AdobeWhileit’swidelyacceptedthatthepharmaindustryisinnovativeinR&D,itisalsotruethatitcanbeslowat